Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
CPI-1189 is a benzamide with neuroprotective and anti-inflammatory activities.1,2,3,4,5 It inhibits phosphorylation of p38 MAPK in IL-1β-stimulated primary rat astrocytes by 70 to 80% when used at concentrations ranging from 10 to 300 nM.1 CPI-1189 (20 mg/kg per day) reduces TNF-α-induced apoptosis in the corpus callosum and septum, but not in the neocortex or basal ganglia, as well as reduces TNF-α-induced decreases in GFAP levels in isolated rat brain slices.2 It decreases the latency to find the platform in the Morris water maze, indicating reversal of memory deficits, induced by TNF-α in a rat model of AIDS dementia when administered at a dose of 20 mg/kg per day.3 CPI-1189 (30 mg/kg per day) reduces crypt loss and decreases the number of ulcers and inflammatory cells in colonic lesions in mouse models of colitis induced by TNBS or dextran sulfate sodium (DSS; Item No. 23250).4,5
WARNING This product is not for human or veterinary use.
1. CPI-
2. CPI-
3. Preventive actions of a synthetic antioxidant in a novel animal model of AIDS dementia. Brain Res. 795(1-2), 349-357 (1998).
4. CPI-
5. CPI-